OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	77
Your chemo is no good here: management of high-risk MCL	76
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	68
Bispecific antibody therapies	50
Labor and delivery: DIC, HELLP, preeclampsia	47
Anticoagulation at the end of life: whether, when, and how to treat	40
Inpatient recognition and management of HLH	39
Neurological manifestations of MGUS	38
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	36
Mastocytosis demystified	35
On the horizon: upcoming new agents for the management of ITP	35
Diagnosis and therapeutic decision-making for the neutropenic patient	33
Recognizing, defining, and managing CAR-T hematologic toxicities	32
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	31
Has PD-1 blockade changed the standard of care for cHL?	31
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	26
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	26
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	26
Divergent paths: management of early relapsed follicular lymphoma	26
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	26
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	26
Selecting initial therapy in CLL	25
Troubleshooting heparin resistance	25
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	24
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	24

Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	23
How to assess hemostasis in patients with severe liver disease	23
Optimizing outcomes in secondary AML	23
New approaches to tackle cytopenic myelofibrosis	23
BV and beyond: how to incorporate novel agents into PTCL management	23
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	22
MGCS: where do we stand today?	21
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	21
How to recognize and manage COVID-19-associated coagulopathy	21
Fitness and frailty in myeloma	21
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	21
How to manage hemostasis in patients with liver disease during interventions	21
Running interferon interference in treating PV/ET: meeting unmet needs	20
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	20
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	20
Consumptive coagulopathy in the ICU	20
Management of TKI-resistant chronic phase CML	20
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	19
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	19
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	19
How to diagnose and manage antiphospholipid syndrome	19
Hemophilia gene therapy: ushering in a new treatment paradigm?	19
Managing therapy-associated neurotoxicity in children with ALL	18
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	18
Special considerations in GI bleeding in VWD patients	18
Atypical CML: diagnosis and treatment	18
Demystifying autoimmune HIT: what it is, when to test, and how to treat	18
Management of marginal zone lymphomas	18
Hematology 2022—what is complete HLA match in 2022?	18
Thrombosis questions from the inpatient wards	17
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	17
Approaches to management of HIT in complex scenarios, including cardiac surgery	17
What to use to treat AML: the role of emerging therapies	17
How to manage bleeding disorders in aging patients needing surgery	17
Management of limited-stage Hodgkin lymphoma	17
Lower risk but high risk	16
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	16
Infectious complications and vaccines	16
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	15
CNS prophylaxis in aggressive B-cell lymphoma	15
Thrombocytopenia in pregnancy	14
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	14
Organ function indications and potential improvements following curative therapy for sickle cell disease	14
When does a PNH clone have clinical significance?	14
Treatment of VTE in the thrombocytopenic cancer patient	14
Transplant in AML with measurable residual disease: proceed or defer?	14
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	14
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	14
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	14
Alloimmunization and hyperhemolysis in sickle cell disease	14

Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	14
What makes a pediatric or young adult patient an appropriate transplant candidate?	13
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	13
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	13
Pegylated interferon: the who, why, and how	13
Next-generation therapy for lower-risk MDS	13
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	13
Ph− ALL: immunotherapy in upfront treatment	13
Cytoreduction for ET and PV: who, what, when, and how?	13
Clinical manifestations of telomere biology disorders in adults	12
What is the ideal approach—doublet, triplet, or quadruplet(s)?	12
Should we use bisphosphonates to treat bone complications in sickle cell disease?	12
Novel therapies upon failure of HMA plus venetoclax	12
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	12
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	12
The role of stem cell transplant (auto and allo) in PTCL and CTCL	12
Managing side effects: guidance for use of immunotherapies in multiple myeloma	12
Frontline treatment in CLL: the case for time-limited treatment	12
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	12
Whom should we treat with novel agents? Specific indications for specific and challenging populations	12
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	12
What else do I need to worry about when treating graft-versus-host disease?	12
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	11
Warm autoimmune hemolytic anemia and the best treatment strategies	11
Treatment of older adult or frail patients with multiple myeloma	11
von Willebrand disease and heavy menstrual bleeding: when and how to test	11
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	11
IV iron formulations and use in adults	11
In 2022, which is preferred: haploidentical or cord transplant?	11
Diamond-Blackfan anemia	11
Immunology 101: fundamental immunology for the practicing hematologist	11
Sequencing bispecific antibodies and CAR T cells for FL	11
Approach to the patient with suspected hypereosinophilic syndrome	11
Barriers to accessing cellular therapy for patients receiving care in community practices	11
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	11
Porphyria cutanea tarda: a unique iron-related disorder	11